Overview
- At 12 weeks, Eupraxia reports patients receiving 8 mg per injection site showed near‑complete normalization of esophageal tissue on biopsy.
- At 36 weeks, patients in the 4 mg per site cohorts maintained the tissue health improvements observed at week 12.
- Among patients with at least 60% of the esophagus treated, the company reports clinical remission rates of 58% at 12 weeks (n=19), 79% at 24 weeks (n=14), and 67% at 52 weeks (n=6).
- Across 31 patients and more than 200 patient‑months of follow‑up, Eupraxia reports no serious adverse events and no oral candidiasis, with EP‑104GI described as well tolerated.
- The Phase 1b/2a RESOLVE study is an open‑label, single‑dose, dose‑escalation trial delivered via 4 to 20 esophageal wall injections, and Eupraxia observed a dose‑response in EoEHSS Grade and Stage.